210 related articles for article (PubMed ID: 26152221)
1. Influence of glycemic control on gain in VO2 peak, in patients with type 2 diabetes enrolled in cardiac rehabilitation after an acute coronary syndrome. The prospective DARE study.
Vergès B; Patois-Vergès B; Iliou MC; Simoneau-Robin I; Bertrand JH; Feige JM; Douard H; Catargi B; Fischbach M;
BMC Cardiovasc Disord; 2015 Jul; 15():64. PubMed ID: 26152221
[TBL] [Abstract][Full Text] [Related]
2. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
3. Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.
Del Olmo-García MI; Hervás Marín D; Caudet Esteban J; Ballesteros Martin-Portugués A; Cerveró Rubio A; Arnau Vives MA; Catalá Gregori A; Penalba Martínez M; Merino-Torres JF
J Int Med Res; 2020 Jun; 48(6):300060520926063. PubMed ID: 32567433
[TBL] [Abstract][Full Text] [Related]
4. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
6. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
[TBL] [Abstract][Full Text] [Related]
8. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
12. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
13. Results of a Study Comparing Glycated Albumin to Other Glycemic Indices.
Desouza CV; Holcomb RG; Rosenstock J; Frias JP; Hsia SH; Klein EJ; Zhou R; Kohzuma T; Fonseca VA
J Clin Endocrinol Metab; 2020 Mar; 105(3):677-87. PubMed ID: 31650161
[TBL] [Abstract][Full Text] [Related]
14. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
[TBL] [Abstract][Full Text] [Related]
16. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
[TBL] [Abstract][Full Text] [Related]
17. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436
[No Abstract] [Full Text] [Related]
18. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial.
Pradhan AD; Everett BM; Cook NR; Rifai N; Ridker PM
JAMA; 2009 Sep; 302(11):1186-94. PubMed ID: 19755697
[TBL] [Abstract][Full Text] [Related]
19. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
20. Does Preoperative Glycemic Control Restore Immune Defense Against Implant-related Infection in Mice With Diabetes?
Lin J; Huang T; Wei H; Bao B; Gao T; Zheng X; Zhu H
Clin Orthop Relat Res; 2022 May; 480(5):1008-1017. PubMed ID: 34797251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
